Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Bruceantin shows promise in prostate treatment-resistant prostate cancer

Key clinical point: The antimalarial agent bruceantin inhibited full length aberrant androgen receptor (AR-FL) and AR variant 7 (AR-V7) in cell cultures of castration-resistant prostate cancer.

Major finding: Bruceantin demonstrated binding to the protein and molecular chaperone HSP90, which prevented the interaction of HSP90 and AR-FL/AR-V7 that contributes to treatment resistance in prostate cancer.

Study details: The data come from an assay test of antimalarial agents including bruceantin (BCT) as potential treatments for castration-resistant prostate cancer.

Disclosures: The study was supported by the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare; and the National Research Foundation of Korea (NRF) grant funded by the Ministry of Science and ICT (MSIT). The researchers had no financial conflicts to disclose.


Moon SJ et al. Theranostics. 2021 Jan 1. doi: 10.7150/thno.51478.